Bausch Health Sues Norwich for Patent Infringement Over Application for Generic Version of IBS Drug

MT Newswires Live06-21

Bausch Health Companies (BHC) and its Salix Pharmaceuticals gastroenterology business said Thursday they have filed a patent infringement lawsuit against Alvogen subsidiary Norwich Pharmaceuticals over its attempt to market a generic version of Salix's diarrhea-predominant irritable bowel syndrome treatment Xifaxan..

The lawsuit filed in the US District Court for the District of New Jersey is in connection with Norwich's amendment to an Abbreviated New Drug Application to the US Food and Drug Administration requesting approval to market a generic version of the drug, also known as rifaximin.

Basuch said the US District Court for the District of Delaware in 2022 issued a ruling that barred Norwich's first Abbreviated New Drug Application for a generic version of the drug until October 2029.

Norwich's parent company Alvogen did not immediately reply to MT Newswires' request for comment.

Price: 6.75, Change: +0.02, Percent Change: +0.30

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2445736048?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-21 17:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2445736048","market":"hk","top_or_hot":-1,"title":"Bausch Health Sues Norwich for Patent Infringement Over Application for Generic Version of IBS Drug","media":"MT Newswires Live","content":"<html><body><p> Bausch Health Companies (BHC) and its Salix Pharmaceuticals gastroenterology business said Thursday they have filed a patent infringement lawsuit against Alvogen subsidiary Norwich Pharmaceuticals over its attempt to market a generic version of Salix's diarrhea-predominant irritable bowel syndrome treatment Xifaxan.. </p><p>The lawsuit filed in the US District Court for the District of New Jersey is in connection with Norwich's amendment to an Abbreviated New Drug Application to the US Food and Drug Administration requesting approval to market a generic version of the drug, also known as rifaximin.</p><p>Basuch said the US District Court for the District of Delaware in 2022 issued a ruling that barred Norwich's first Abbreviated New Drug Application for a generic version of the drug until October 2029.</p><p>Norwich's parent company Alvogen did not immediately reply to MT Newswires' request for comment.</p><p>Price: 6.75, Change: +0.02, Percent Change: +0.30</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bausch Health Sues Norwich for Patent Infringement Over Application for Generic Version of IBS Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBausch Health Sues Norwich for Patent Infringement Over Application for Generic Version of IBS Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-21 17:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bausch Health Companies (BHC) and its Salix Pharmaceuticals gastroenterology business said Thursday they have filed a patent infringement lawsuit against Alvogen subsidiary Norwich Pharmaceuticals ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BHC","symbol_name":"Bausch Health Companies Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2445736048","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2445736048","pubTimestamp":1718961450,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Bausch Health Companies  and its Salix Pharmaceuticals gastroenterology business said Thursday they have filed a patent infringement lawsuit against Alvogen subsidiary Norwich Pharmaceuticals over its attempt to market a generic version of Salix's diarrhea-predominant irritable bowel syndrome treatment Xifaxan.. The lawsuit filed in the US District Court for the District of New Jersey is in connection with Norwich's amendment to an Abbreviated New Drug Application to the US Food and Drug Administration requesting approval to market a generic version of the drug, also known as rifaximin.Basuch said the US District Court for the District of Delaware in 2022 issued a ruling that barred Norwich's first Abbreviated New Drug Application for a generic version of the drug until October 2029.Norwich's parent company Alvogen did not immediately reply to MT Newswires' request for comment.Price: 6.75, Change: +0.02, Percent Change: +0.30","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BHC":"Bausch Health Companies Inc","BK4007":"制药"},"translate_title":"Bausch Health起诉Norwich申请IBS药物仿制药专利侵权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHC":0.9},"content_text":"Bausch Health Companies (BHC) and its Salix Pharmaceuticals gastroenterology business said Thursday they have filed a patent infringement lawsuit against Alvogen subsidiary Norwich Pharmaceuticals over its attempt to market a generic version of Salix's diarrhea-predominant irritable bowel syndrome treatment Xifaxan.. The lawsuit filed in the US District Court for the District of New Jersey is in connection with Norwich's amendment to an Abbreviated New Drug Application to the US Food and Drug Administration requesting approval to market a generic version of the drug, also known as rifaximin.Basuch said the US District Court for the District of Delaware in 2022 issued a ruling that barred Norwich's first Abbreviated New Drug Application for a generic version of the drug until October 2029.Norwich's parent company Alvogen did not immediately reply to MT Newswires' request for comment.Price: 6.75, Change: +0.02, Percent Change: +0.30","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2445736048"}